series-c-plus
Stage
1
Investors
About
Mirati Therapeutics is a clinical-stage biotechnology company developing targeted oncology therapies, including KRAS G12C inhibitors; its lead program is adagrasib (KRAZATI) for KRAS G12C-mutated cancers.
Explore Mirati Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.